ClinicalTrials.gg
RecruitingNCT07167550Updated Sep 11, 2025

The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke

A Phase 3 interventional study of Dimephosphon® and Placebo in Stroke, Acute Stroke and Ischemic Stroke, sponsored by Tatchempharmpreparaty, JSC. Recruiting at 6 sites in Russia. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-11.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's listed conditions name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Tatchempharmpreparaty, JSC · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
35 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Ischemic Stroke with a site in Russia — 13 open to participants now, 13 under way, 2 of them phase 3. Ischemic Stroke · Russia.

Started
2025
with 2 others
Phase 3
3 of 17
2 open now
Primary completion
2026-01
later than 0 of 12 live
Registered
11th of 17
by date

Among the 17 studies in Ischemic Stroke with a site in Russia, this one is one of 3 that started in 2025, is one of 3 in phase 3, reaches primary completion later than 0 of the 12 other live ones, and was the 11th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

13 of the 17 studies in Ischemic Stroke with a site in Russia are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 35 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Ischemic Stroke with a site in Russia, or all of them as a file.
02

Study summary

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dimephosphon® in acute ischemic stroke

Read the detailed description

This study is a multicenter, randomized, double-blind, placebo-controlled trial. The purpose of the study is to evaluate the efficacy and safety of Dimephosphon® in acute ischemic stroke. The study includes a screening period (Visit 1, up to 48 hours) and a treatment period (Visits 2-4). Subjects will be randomized into 2 groups in a 1:1 ratio: Group A (investigational drug Dimephosphon®) and Group B (placebo). Key inclusion criteria: verified by CT/MRI current hemispheric ischemic stroke, NIHSS score ≥5 and ≤15 at screening. The study will assess clinical outcomes using standardized scales including NIHSS, mRS, MMSE, MoCA and EQ-5D.

03

Conditions studied

  • Stroke
  • Acute Stroke
  • Ischemic Stroke
  • Cerebrovascular Disorders
  • Physiological Effects of Drugs

Browse trials for

Keywords

  • Neuroprotective Agents
  • Protective Agents
  • Neuroprotection
  • Anti-acidemic agents
  • Dimephosphon
  • Dimethyloxobutylphosphonyldimethylate
  • Acute Stroke
  • Ischemic Stroke
  • Antioxidants
04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 184 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

This is the only study on the registry with Tatchempharmpreparaty, JSC as lead sponsor.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written was obtained from the patient or their legally authorized representative prior to study participation.
  2. Age 35-80.
  3. Patients must exhibit neurological manifestations consistent with acute ischemic stroke, with a documented onset-to-intervention interval ranging from 24 to 72 hours at the time of scheduled initial administration of the drug.
  4. Verified by CT/MRI current hemispheric ischemic stroke.
  5. NIHSS score ≥5 and ≤15 at screening.
  6. Ability to comply with all protocol-specified procedures, prohibitions, and restrictions.
  7. Willingness and ability to adhere to highly effective methods as outlined in the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Hemorrhagic stroke or hemorrhagic transformation of ischemic focus, traumatic brain injuries
  2. Vertebrobasilar stroke and/or development of acute insufficiency syndromes in the arteries of the vertebrobasilar system
  3. A patient with ischemic stroke who is a candidate for reperfusion therapy or who has undergone reperfusion therapy before participation in this study.
  4. The presence of anatomical abnormalities of the cerebral vessels (arteriovenous malformations, cavernous malformations, aneurysms, atresia of at least one of the extracranial arteries) according to the anamnesis or CT/MRI data.
  5. Progression of neurological symptoms of stroke, defined as an increase in the NIHSS score by 4 points at the second assessment (immediately before randomization) from the value obtained at the first assessment (immediately after signing the form).
  6. Surgery on the carotid arteries less than 1 year before screening.
  7. History of stroke less than 1 year before screening.
  8. Myocardial infarction less than 6 months before screening.
  9. Chronic renal failure stage 2-3 ( less than 40 ml/min).
  10. Pregnancy or lactation.
  11. Participation in another trial within 28 days prior to enrollment.
  12. Use of prohibited medications.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
184 participants (estimated)

Study arms

  • Experimental
    Dimephosphon®

    Days 1-3: Dimephosphon® 2 g (2 vials) administered as intravenous infusion diluted in 200 mL of 0.9% sodium chloride solution three times daily (morning, afternoon, and evening, with minimum 5-hour interval between administrations). Days 4-14: Dimephosphon® 2 g (2 vials) administered as intravenous bolus diluted in 20 mL of 0.9% sodium chloride solution three times daily (morning, afternoon, and evening, with minimum 5-hour interval between administrations).

    Drug: Dimephosphon®

  • Placebo comparator
    Placebo

    Days 1-3: Placebo 2 g (2 vials) administered as intravenous infusion diluted in 200 mL of 0.9% sodium chloride solution three times daily (morning, afternoon, and evening, with minimum 5-hour interval between administrations). Days 4-14: Placebo 2 g (2 vials) administered as intravenous bolus diluted in 20 mL of 0.9% sodium chloride solution three times daily (morning, afternoon, and evening, with minimum 5-hour interval between administrations).

    Drug: Placebo

Interventions

  • DrugDimephosphon®

    1 g/ml, concentrate for solution for intravenous infusion

  • DrugPlacebo

    Placebo IV solution

07

What researchers measure

Primary outcomes

  1. Percentage of subjects having Modified Rankin Scale (mRS) scores 0-2 at Visit 4 (Day 15)

    Time frame: Day 15

Secondary outcomes

  1. Percentage of subjects having Modified Rankin Scale (mRS) scores 0-2 at Visit 3 (Day 8), Visit 5 (Day 30), Visit 6 (Day 90).

    Time frame: Day 8, Day 30, Day 90

  2. Change from Baseline (Visit 1, no more than 48 hours) in the National Institutes of Health Stroke Scale (NIHSS) score at Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 30), Visit 6 (Day 90).

    Time frame: Baseline, Day 8, Visit 4 Day 15, Day 30, Day 90

  3. Percentage of subjects with changes from Baseline (Visit 1, no more than 48 hours) in NIHSS score at Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 30), Visit 6 (Day 90).

    Time frame: Baseline, Day 8, Day 15, Day 30, Day 90

  4. Proportion of patients with a ≥4-point change in NIHSS score from Baseline (Visit 1, no more than 48 hours) at Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 30), and Visit 6 (Day 90).

    Time frame: Baseline, Day 8, Day 15, Day 30, Day 90

  5. Proportion of patients with a ≥2-point change in NIHSS score from Baseline (Visit 1, no more than 48 hours) to Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 30), Visit 6 (Day 90).

    Time frame: Baseline, Day 8, Day 15, Day 30, Day 90

  6. Change from Baseline (Visit 1, no more than 48 hours) in the Montreal Cognitive Assessment (MoCA) score at Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 30), Visit 6 (Day 90).

    Time frame: Baseline, Day 8, Day 15, Day 30, Day 90

  7. Change from Baseline (Visit 1, no more than 48 hours) in the Mini-Mental State Examination (MMSE) score at Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 30), Visit 6 (Day 90).

    Time frame: Baseline, Day 8, Day 15, Day 30, Day 90

  8. Change from Baseline (Visit 1, no more than 48 hours) in the EuroQol 5-Dimensions (EQ-5D) score at Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 30), Visit 6 (Day 90).

    Time frame: Baseline, Day 8, Day 15, Day 30, Day 90

  9. All-cause mortality from Visit 2 to Visit 6 (Hazard Ratio)

    Time frame: up to Day 90

08

Study locations

5 of 6 sites recruiting
  • State Budgetary Healthcare Institution of the Leningrad Region "Vsevolozhsk Interdistrict Clinical Hospital
    Vsevolozhsk, Leningradskaya Oblast' 188643, Russia
    Recruiting
  • State Budgetary Healthcare Institution "Research Institute - Regional Clinical Hospital No. 1 named after Professor S.V. Ochapovsky" of the Ministry of Health of the Krasnodar region
    Krasnodar, 350086, Russia
    Not yet recruiting
  • Federal State Autonomous Educational Institution of Higher Education "Peoples' Friendship University of Russia named after Patrice Lumumba"
    Moscow, 117198, Russia
    Recruiting
  • The FSBI "Federal Center of Brain Research and Neurotechnologies" of the Federal Medical and Biological Agency
    Moscow, 117513, Russia
    Recruiting
  • Saint Petersburg State Budgetary Healthcare Institution "City Hospital No. 40 of the Kurortny District"
    Saint Petersburg, 197706, Russia
    Recruiting
  • State Budgetary Healthcare Institution "City Hospital No. 4 of Sochi" of the Ministry of Healthcare of the Krasnodar Region
    Sochi, 354057, Russia
    Recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Jan 2026, 4 months later.

Of 167 phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 11, 2025
StartEst.
Sep 6, 2025
Primary completionEst.
Jan 31, 2026
CompletionEst.
Apr 30, 2026
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07167550
Lead sponsor
Tatchempharmpreparaty, JSC
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Sep 6, 2025 (estimated)
Primary completion
Jan 31, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Sep 11, 2025

Study contacts

Alfiya Fakhrieva
Contact
iksanova@tatpharm.ru
+78435269764
Alyona Tirskaya
Contact
atirskaya@x7research.ru
+7812309847

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion